Okayama nephrotic syndrome treatment group: Study group for short-term combination therapy of angiotensin-2 receptor blocker and cyclosporine for keeping remission

UMIN ID: UMIN000000621

Registered date:28/02/2007

Basic Information

• Recruitment status: Complete: follow-up complete
• Health condition(s) or Problem(s) studied: Minimal change nephrotic syndrome
• Date of first enrollment: 2007/03/01
• Target sample size: 50
• Countries of recruitment: Japan
• Study type: Interventional

Intervention(s)

Prednisolone (+), combination therapy (-)
Prednisolone (+), combination therapy (+)

Outcome(s)

• Primary Outcome: The number of relapse after initial treatment and the duration of remission before the relapse

Key inclusion & exclusion criteria

• Age minimum: 16years-old
• Age maximum: Not applicable
• Gender: Male and Female
• Exclude criteria: 1) Renal dysfunction (Ccr under 30 ml/min) 2) Histry of taking immunosuppressant within one month 3) Patients with malignant disease 4) Malabsorption syndrome or epilepsy 5) Severe heart, liver, or pancreatic disaese 6) Active infectious disease 7) Pregnancy 8) Hypersensitivity to cyclosporin 9) Hypersensitivity to ARB 10) Patients with FSGS 11) Others

Related Information

• Primary Sponsor: Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan
• Source(s) of Monetary Support: Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan